FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 341:1606-1609 November 18, 1999 Number 21 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Singhal, S. PubMed Citation

One of the most devastating tragedies of modern medicine was set into motion by the over-the-counter marketing of thalidomide in Europe during the late 1950s for the treatment of morning sickness. The drug was withdrawn in the 1960s after the appearance of reports of teratogenicity and phocomelia associated with its use. The recent return of thalidomide stems from the broad spectrum of its pharmacologic and immunologic effects.¹ Thalidomide has been approved by the Food and Drug Administration for the treatment of erythema nodosum leprosum, an inflammatory manifestation of leprosy,² and potential therapeutic applications span a wide spectrum of other diseases.

. . . [Full Text of this Article]

References

Related Letters:

Thalidomide in Multiple Myeloma
Kishi Y., Oki Y., Machida U., Barlogie B.
Extract | Full Text  
N Engl J Med 2000; 342:975-976, Mar 30, 2000. Correspondence

This article has been cited by other articles:

• Faria, S. C., Ng, C. S., Hess, K. R., Phongkitkarun, S., Szejnfeld, J., Daliani, D., Charnsangavej, C. (2007). CT Quantification of Effects of Thalidomide in Patients with Metastatic Renal Cell Carcinoma. Am. J. Roentgenol. 189: 378-385 [Abstract] [Full Text]  
• Kiziltepe, T., Hideshima, T., Ishitsuka, K., Ocio, E. M., Raje, N., Catley, L., Li, C.-Q., Trudel, L. J., Yasui, H., Vallet, S., Kutok, J. L., Chauhan, D., Mitsiades, C. S., Saavedra, J. E., Wogan, G. N., Keefer, L. K., Shami, P. J., Anderson, K. C. (2007). JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells. Blood 110: 709-718 [Abstract] [Full Text]  
• Kang, T. Y., Lowe, C. J., Sekeres, M. A. (2006). Thalidomide Use and Digital Gangrene. JCO 24: 5328-5328 [Full Text]  
• Onozawa, M., Hashino, S., Sogabe, S., Haneda, M., Horimoto, H., Izumiyama, K., Kondo, T., Aldana, L. P., Hamada, K., Asaka, M. (2005). Side Effects and Good Effects from New Chemotherapeutic Agents: CASE 2. Thalidomide-Induced Interstitial Pneumonitis. JCO 23: 2425-2426 [Full Text]  
• Kaufmann, H., Raderer, M., Wohrer, S., Puspok, A., Bankier, A., Zielinski, C., Chott, A., Drach, J. (2004). Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood 104: 2269-2271 [Abstract] [Full Text]  
• Park, S.-J., Kim, H.-S., Yang, H.-M., Park, K.-W., Youn, S.-W., Jeon, S.-I., Kim, D.-H., Koo, B.-K., Chae, I.-H., Choi, D.-J., Oh, B.-H., Lee, M.-M., Park, Y.-B. (2004). Thalidomide as a Potent Inhibitor of Neointimal Hyperplasia After Balloon Injury in Rat Carotid Artery. Arterioscler. Thromb. Vasc. Bio. 24: 885-891 [Abstract] [Full Text]  
• Hussein, M. A. (2003). Modifications to Therapy for Multiple Myeloma: Pegylated Liposomal Doxorubicin in Combination With Vincristine, Reduced-Dose Dexamethasone, and Thalidomide. The Oncologist 8: 39-45 [Abstract] [Full Text]  
• Drucker, L., Uziel, O., Tohami, T., Shapiro, H., Radnay, J., Yarkoni, S., Lahav, M., Lishner, M. (2003). Thalidomide Down-Regulates Transcript Levels of GC-Rich Promoter Genes in Multiple Myeloma. Mol. Pharmacol. 64: 415-420 [Abstract] [Full Text]  
• Weeber, M., Vos, R., Klein, H., de Jong-van den Berg, L. T.W., Aronson, A. R., Molema, G. (2003). Generating Hypotheses by Discovering Implicit Associations in the Literature: A Case Report of a Search for New Potential Therapeutic Uses for Thalidomide. J. Am. Med. Inform. Assoc. 10: 252-259 [Abstract] [Full Text]  
• Marriott, J. B., Clarke, I. A., Czajka, A., Dredge, K., Childs, K., Man, H.-W., Schafer, P., Govinda, S., Muller, G. W., Stirling, D. I., Dalgleish, A. G. (2003). A Novel Subclass of Thalidomide Analogue with Anti-Solid Tumor Activity in Which Caspase-dependent Apoptosis is Associated with Altered Expression of bcl-2 Family Proteins. Cancer Res. 63: 593-599 [Abstract] [Full Text]  
• Neben, K., Moehler, T., Benner, A., Kraemer, A., Egerer, G., Ho, A. D., Goldschmidt, H. (2002). Dose-dependent Effect of Thalidomide on Overall Survival in Relapsed Multiple Myeloma. Clin. Cancer Res. 8: 3377-3382 [Abstract] [Full Text]  
• Fiegl, M., Greil, R., Montoto, S., Blade, J., Montserrat, E., Jokl, D. H.-K., Kyle, R. A., Rajkumar, S. V., Melton, J. III (2002). Monoclonal Gammopathy of Undetermined Significance. NEJM 346: 2087-2088 [Full Text]  
• Hlatky, L., Hahnfeldt, P., Folkman, J. (2002). Clinical Application of Antiangiogenic Therapy: Microvessel Density, What It Does and Doesn't Tell Us. JNCI J Natl Cancer Inst 94: 883-893 [Full Text]  
• Dredge, K., Marriott, J. B., Todryk, S. M., Muller, G. W., Chen, R., Stirling, D. I., Dalgleish, A. G. (2002). Protective Antitumor Immunity Induced by a Costimulatory Thalidomide Analog in Conjunction with Whole Tumor Cell Vaccination Is Mediated by Increased Th1-Type Immunity. J. Immunol. 168: 4914-4919 [Abstract] [Full Text]  
• Hideshima, T., Chauhan, D., Richardson, P., Mitsiades, C., Mitsiades, N., Hayashi, T., Munshi, N., Dang, L., Castro, A., Palombella, V., Adams, J., Anderson, K. C. (2002). NF-kappa B as a Therapeutic Target in Multiple Myeloma. J. Biol. Chem. 277: 16639-16647 [Abstract] [Full Text]  
• Cohen, D., McCubbin, M., Collin, J., Perodeau, G. (2001). Medications as Social Phenomena. Health (London) 5: 441-469 [Abstract]  
• Kerbel, R. S. (2001). Clinical Trials of Antiangiogenic Drugs: Opportunities, Problems, and Assessment of Initial Results. JCO 19: 45s-51 [Full Text]  
• Neben, K., Moehler, T., Egerer, G., Kraemer, A., Hillengass, J., Benner, A., Ho, A. D., Goldschmidt, H. (2001). High Plasma Basic Fibroblast Growth Factor Concentration Is Associated with Response to Thalidomide in Progressive Multiple Myeloma. Clin. Cancer Res. 7: 2675-2681 [Abstract] [Full Text]  
• Vincent Rajkumar, S., Kyle, R. A. (2001). Thalidomide in the Treatment of Plasma Cell Malignancies. JCO 19: 3593-3595 [Full Text]  
• Dimopoulos, M. A., Zomas, A., Viniou, N. A., Grigoraki, V., Galani, E., Matsouka, C., Economou, O., Anagnostopoulos, N., Panayiotidis, P. (2001). Treatment of Waldenstrom's Macroglobulinemia With Thalidomide. JCO 19: 3596-3601 [Abstract] [Full Text]  
• Podar, K., Tai, Y.-T., Davies, F. E., Lentzsch, S., Sattler, M., Hideshima, T., Lin, B. K., Gupta, D., Shima, Y., Chauhan, D., Mitsiades, C., Raje, N., Richardson, P., Anderson, K. C. (2001). Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 98: 428-435 [Abstract] [Full Text]  
• Barlogie, B., Desikan, R., Eddlemon, P., Spencer, T., Zeldis, J., Munshi, N., Badros, A., Zangari, M., Anaissie, E., Epstein, J., Shaughnessy, J., Ayers, D., Spoon, D., Tricot, G. (2001). Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 98: 492-494 [Abstract] [Full Text]  
• Dalton, W. S., Bergsagel, P. L., Kuehl, W. M., Anderson, K. C., Harousseau, J. L. (2001). Multiple Myeloma. ASH Education Book 2001: 157-177 [Abstract] [Full Text]  
• Hideshima, T., Chauhan, D., Shima, Y., Raje, N., Davies, F. E., Tai, Y.-T., Treon, S. P., Lin, B., Schlossman, R. L., Richardson, P., Muller, G., Stirling, D. I., Anderson, K. C. (2000). Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96: 2943-2950 [Abstract] [Full Text]  
• Raje, N., Anderson, K. C. (2000). Introduction: the evolving role of bisphosphonate therapy in multiple myeloma. Blood 96: 381-383 [Full Text]  
• Davey, P.P., Ashrafian, H. (2000). New therapies for heart failure: is thalidomide the answer?. QJM 93: 305-311 [Abstract] [Full Text]  
• Kishi, Y., Oki, Y., Machida, U., Barlogie, B. (2000). Thalidomide in Multiple Myeloma. NEJM 342: 975-976 [Full Text]  
• Anderson, K. C., Kyle, R. A., Dalton, W. S., Landowski, T., Shain, K., Jove, R., Hazlehurst, L., Berenson, J. (2000). Multiple Myeloma: New Insights and Therapeutic Approaches. ASH Education Book 2000: 147-165 [Abstract] [Full Text]  
• (1999). Thalidomide in Refractory Multiple Myeloma. JWatch General 1999: 3-3 [Full Text]